Targeted over-expression of endothelin-1 in astrocytes leads to more severe brain damage and vasospasm after subarachnoid hemorrhage
Open Access
- 25 October 2013
- journal article
- research article
- Published by Springer Nature in BMC Neuroscience
- Vol. 14 (1) , 131
Abstract
Background: Endothelin-1 (ET-1) is a potent vasoconstrictor, and astrocytic ET-1 is reported to play a role in the pathogenesis of cerebral ischemic injury and cytotoxic edema. However, it is still unknown whether astrocytic ET-1 also contributes to vasogenic edema and vasospasm during subarachnoid hemorrhage (SAH). In the present study, transgenic mice with astrocytic endothelin-1 over-expression (GET-1 mice) were used to investigate the pathophysiological role of ET-1 in SAH pathogenesis.Results: The GET-1 mice experienced a higher mortality rate and significantly more severe neurological deficits, blood–brain barrier breakdown and vasogenic edema compared to the non-transgenic (Ntg) mice following SAH. Oral administration of vasopressin V1areceptor antagonist, SR 49059, significantly reduced the cerebral water content in the GET-1 mice. Furthermore, the GET-1 mice showed significantly more pronounced middle cerebral arterial (MCA) constriction after SAH. Immunocytochemical analysis showed that the calcium-activated potassium channels and the phospho-eNOS were significantly downregulated, whereas PKC-α expression was significantly upregulated in the MCA of the GET-1 mice when compared to Ntg mice after SAH. Administration of ABT-627 (ETAreceptor antagonist) significantly down-regulated PKC-α expression in the MCA of the GET-1 mice following SAH.Conclusions: The present study suggests that astrocytic ET-1 involves in SAH-induced cerebral injury, edema and vasospasm, through ETAreceptor and PKC-mediated potassium channel dysfunction. Administration of ABT-627 (ETAreceptor antagonist) and SR 49059 (vasopressin V1areceptor antagonist) resulted in amelioration of edema and vasospasm in mice following SAH. These data provide a strong rationale to investigate SR 49059 and ABT-627 as therapeutic drugs for the treatment of SAH patients.Keywords
This publication has 81 references indexed in Scilit:
- Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhageBMC Neuroscience, 2013
- Post-treatment with SR49059 Improves Outcomes Following an Intracerebral Hemorrhagic Stroke in Mice2011
- Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injuryNeurochemistry International, 2011
- Temporal profile of potassium channel dysfunction in cerebrovascular smooth muscle after experimental subarachnoid haemorrhageNeuroscience Letters, 2008
- Brain injury-associated biomarkers of TGF-beta1, S100B, GFAP, NF-L, tTG, AbetaPP, and tau were concomitantly enhanced and the UPS was impaired during acute brain injury caused by Toxocara canisin miceBMC Infectious Diseases, 2008
- Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatmentPharmacology & Therapeutics, 2005
- Endothelin receptor antagonists and cerebral vasospasmClinical Autonomic Research, 2004
- Increased endothelin-1 in the rabbit model of middle cerebral artery occlusionNeuroscience Letters, 1994
- BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injectionLife Sciences, 1993
- Endothelin and the production of cerebral vasospasm in dogsBiochemical and Biophysical Research Communications, 1989